Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on oncology therapeutics that reached public markets through its merger with LifeSci Acquisition Corp., a blank-check vehicle sponsored by LifeSci Acquisition LLC that completed its IPO in 2020. The de-SPAC transaction closed in January 2021, bringing Vincerx into the public markets under the biopharmaceutical sector. The company filed an 8-K current report with the SEC on December 27, 2024, under accession number 0001193125-24-285929, disclosing a material corporate event. Investors and analysts seeking full filing history, sponsor details, and deal metrics for VINC and thousands of other SPAC transactions can sign up for complete data access at SpacDesk.